key: cord-0721960-033q671f authors: Cao, C.; Chen, M.; Li, Y.; Yu, L.; Huang, W.; Qian, G.; Zhu, C.; Chu, J.; He, L.; Ma, J.; Chen, X. title: Clinical Features and Predictors for Patients with Severe SARS-CoV-2 Pneumonia: a retrospective multicenter cohort study date: 2020-06-03 journal: nan DOI: 10.1101/2020.06.01.20119032 sha: b226afe2d910a90c2eea5a96abbf18369df48924 doc_id: 721960 cord_uid: 033q671f Objectives: This study was performed to investigate clinical features of patients with severe SARS-CoV-2 pneumonia and identify risk factors for converting to severe cases in those who had mild to moderate diseases. Methods: In this retrospective, multicenter cohort study, patients with mild to moderate SARS-CoV-2 pneumonia were included. Demographic data, symptoms, laboratory values, and clinical outcomes were collected. Data were compared between non-severe and severe patients. Results: 58 patients were included in the final analysis. Compared with non-severe cases, severe patients with SARS-CoV-2 pneumonia had a longer: time to clinical recovery (p=0.0011), duration of viral shedding (p=0.0183), and hospital stay ( p=0.0211). Multivariate logistic regression indicated that lymphocyte count was significantly associated with the rate of converting to severe cases (odds ratio 1.28, 95%CI 1.06-1.54, per 0.1*10 9/L reduced; p=0.007), while using of low-to-moderate doses of systematic corticosteroids was associated with reduced likelihood of converting to a severe case (odds ratio 0.14, 95%CI 0.02-0.80; p=0.0275). Conclusions: The low peripheral blood lymphocyte count was an independent risk factor for SARS-CoV-2 pneumonia patients converting to severe cases. This finding may help clinicians more accurately predict prognosis, and triage priorities to improve clinical outcomes. Background: Starting from early December 2019, cases of human infection with a novel coronavirus were identified in Wuhan, Hubei Province, China. It spreads rapidly to other cities and numerous countries. This study was performed to investigate clinical features of patients with severe SARS-CoV-2 pneumonia and identify risk factors for converting to severe cases in those who had mild to moderate diseases. Methods: In this retrospective, multicenter cohort study, patients with mild to moderate SARS-CoV-2 pneumonia were included from Ningbo First Hospital and Jingzhou Central Hospital. Demographic data, symptoms, laboratory values, comorbidities, and clinical outcomes were collected. Data were compared between non-severe and severe patients. Logistic regression analysis was performed to assess risk factors in predicting the patients with SARS-CoV-2 pneumonia who would convert to severe cases. Hospital) were included in this study, among which 62 were excluded and 58 were included in the final analysis. Compared with non-severe cases, severe patients with SARS-CoV-2 pneumonia had a longer: time to clinical recovery (12·9±4·4 vs 8·3±4·7; p=0·0011), duration of viral shedding (15·7±6·7 vs 11·8±5·0; p=0·0183), and hospital stay (20·7±1·2 vs 14·4±4·3; p=0·0211). Multivariate logistic regression indicated that lymphocyte count was significantly associated with the rate of converting to severe cases (odds ratio 1·28, 95%CI 1·06-1·54, per 0·1×10 9 /L reduced; p=0·007), while using of low-to-moderate doses of systematic corticosteroids was associated with reduced likelihood of converting to a severe case (odds ratio 0·14, 95%CI 0·02-0·80; p=0·0275). The low peripheral blood lymphocyte count was an independent risk factor for SARS-CoV-2 pneumonia patients converting to severe cases. This finding may help clinicians more accurately predict prognosis, and triage priorities to improve clinical outcomes. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 3, 2020. . It has been deemed as a public health emergency of global concern by The World Health Organization (WHO). We searched PubMed for articles published up to March 11, 2020, using the search terms ("novel coronavirus" OR "SARS-CoV-2" OR "COVID-19") with no language or time restrictions. Previous work has described clinical characteristics of critically ill and non-critically ill patients with COVID-19. However, no published works have focused on clinical features of patients with severe SARS-CoV-2 pneumonia and identify risk factors for converting to severe cases in those who had mild to moderate diseases. In this retrospective and multicenter cohort study, we reported demographics characteristics, baseline symptoms, laboratory findings, corticosteroid usage and hospital course of patients with non-severe COVID-19 and severe COVID-19. Comparing with non-severe patients, severe patients with COVID-19 was found to have a longer: time to clinical recovery (12.9±4.4 vs 8.3±4.7; p=0.0011), duration of viral shedding (15.7±6.7 vs 11.8±5.0; p=0.0183), and hospital stay (20.7±1.2 vs 14.4±4.3; p=0.0211). By multivariate logistic regression, we found increasing odds of converting to severe cases associated with lower lymphocyte count (odds ratio 1.28, 95%CI 1.06-1.54, per 0.1×10 9 /L reduced; p=0.007). Using of low-to-moderate doses of systematic corticosteroids was associated with reduced likelihood of converting to a severe case (odds ratio 0.14, 95%CI 0.02-0.80; p=0.0275). Low lymphocyte count in peripheral blood was an independent risk factor for patients who converted to severe cases. In addition, using of systematic corticosteroids in mild to moderate patients with SARS-CoV-2 pneumonia was associated with a reduced All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 3, 2020. . https://doi.org/10.1101/2020.06.01.20119032 doi: medRxiv preprint 4 risk of converting to severe cases. These findings may help clinicians predict prognosis more accurately, and triage priorities to improve clinical outcomes. Further prospective studies are warranted to confirm these findings. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 3, 2020. 5 . It is usually accompanied by pneumonia, fever, non-productive cough and asthenia 6 . Nausea, vomiting, and dyspnea are also found in patients with COVID-19, though these are less common 7 suggested that 15·7% of patients had developed severe illness and 1·4% of patients died 6 . Among those severe cases, 43 patients (24·9%) were either admitted to ICU, required mechanical ventilation, or died 6 . The median time from onset of symptoms to shortness of breath, an indicator of severe SARS-CoV-2 pneumonia, was 8 days 7 . It was reported that older patients with comorbidities were more likely to develop severe disease 6, 8 . However, not all older patients with comorbidities convert to severe cases, indicating that there may be other risk factors. Given the rapid spread of SARS-CoV-2 pneumonia and the large threat to public health, this study aims to investigate clinical features and laboratory findings between non-severe and severe patients, thereby exploring predictive factors for severe cases. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 3, 2020. . https://doi.org/10.1101/2020.06.01.20119032 doi: medRxiv preprint This retrospective analysis was conducted using data collected between Jan 21, 2020 and Feb 25, 2020 from Ningbo First Hospital and Jingzhou Central Hospital. Patients with laboratory confirmed diagnoses of SARS-CoV-2 and had been admitted to one of the above medical centers were included. All patients were identified by positive results of reverse transcriptase polymerase chain reaction (RT-PCR) on SARS-CoV-2 in lower respiratory specimens. Patients enrolled presented with mild to moderate SARS-CoV-2 pneumonia at baseline. To avoid potential effects of antiviral drugs, the largest cohort of patients were selected for analysis; all were initiated on combination therapy of arbidol and Kaletra. Ethical approvals for this study were obtained from the Ethics Commission of Ningbo First Hospital (2020-R017) and the Ethics Commission of Jingzhou Central Hospital (2020-2-19). Written informed consent was waived due to the rapid emergence of this disease. Patients' electronic medical records were reviewed to extract the following information retrospectively. The following data were collected: Demographic characteristics: age, gender and history of chronic disease; Symptoms: temperature, cough, dyspnea, score throat, muscle soreness, fatigue, anorexic, nausea and diarrhea; Laboratory assessments on admission: white blood cell count, peripheral blood The severity scores were calculated within 48h of hospital admission. Patients were divided into two cohorts according to the version of Diagnosis and Treatment of All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 3, 2020. and cough (no cough or mild cough). Continuous variables were expressed as mean (SD) or median (IQR) and categorical variables as quantity (proportion). The t-test or Mann-Whitney U test was used for comparison of continuous variables. The chi-squared (χ2) test was used to compare categorical variables. Logistic regression was performed to assess the usefulness of risk factors in predicting the patients with mild to moderate SARS-CoV-2 pneumonia who would convert to severe cases. The following factors were analyzed to determine their effects: age, sex, fever, time from onset of symptoms to antiviral treatment, comorbidities, CRP, PBL, and use of corticosteroids. Odds Ratios (ORs) and 95% confidence intervals (CIs) were estimated. A 2-sided α of <0·05 was considered statistically significant. Statistical analyses were conducted using SPSS version 18·0 (SPSS, Chicago, IL, USA) and SAS version 9·4 (SAS Institute, Cary, North Carolina). Hospital and Jingzhou Central Hospital, among which 58 patients with mild to moderate disease who received the same antiviral drugs were included (figure 1). The All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 3, 2020. . https://doi.org/10.1101/2020.06.01.20119032 doi: medRxiv preprint 8 mean age (SD) of patients was 47·8 years (13·8), where patients aged 40-79 years accounted for 63·8% (table 1) . 30 (51·7%) patients were male. 15 (25·9%) cases had underlying chronic diseases, and 9 (15·5%) had hypertension. Cough (58·6%), fever (41·4%) and fatigue (31·0%) were the most common symptoms at onset, followed by muscle soreness (17·2%) and dyspnea (15·5%). A higher prevalence of comorbidities (34·8% vs 20·0%) was observed in patients who converted to severe cases, and more male patients also converted to severe cases (73·9% vs 37·1%). 25 (43.1%) patients Multivariate logistic regression indicated that lymphopenia (peripheral blood lymphocyte count <1·1×10 9 /L) is an independent risk factors for patients converting to severe cases, with OR value of 8·0 (95%CI, 1·5-41·8) converted to severe cases. The OR for converting to severe cases was 1·28 (95%CI, 1·06-1·54) in patients with a reduced of 0·1×10 9 /L peripheral blood lymphocyte (table 3 ). In addition, the OR for use of corticosteroids in mild to moderate patients with SARS-CoV-2 pneumonia was 0·14 (95%CI, 0·02-0·80) in those who converted to severe cases. The most common symptoms for SARS-CoV-2 pneumonia at onset of illness were fever and cough, but some patients had presence of dyspnea at a median of 8 days All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 3, 2020. . https://doi.org/10.1101/2020.06.01.20119032 doi: medRxiv preprint after onset of illness 9 . Dyspnea, usually observed in severe patients with SARS-CoV-2 pneumonia 10 , may indicate the progression of disease with a low oxygenation index and a state of severe illness. However, up to now, the clinical course of SARS-CoV-2 pneumonia and risk factors for converting to severe cases remain unknown. This study was performed to investigate clinical characteristics of patients with severe SARS-CoV-2 pneumonia, and identify risk factors for those with mild to moderate disease who converted to severe cases. 120 patients (36 from Ningbo First Hospital and 84 from Jingzhou Central Hospital) were included in this study, among which 62 were excluded and 58 were included in the final analysis. The results from this study showed that low peripheral blood lymphocyte count (<1·1×10 9 /L) was an independent risk factor for patients converting to severe cases (OR: 8·0, 95%CI: 1·5-41·8). With each reduction of 0·1×10 9 /L in peripheral blood lymphocyte count, the OR for converting to severe cases increased 28% (95%CI, 6%-54%). In addition, using of corticosteroids in mild to moderate patients with SARS-CoV-2 pneumonia was also associated with a reduced risk of converting to severe cases (OR: 0·14, 95%CI: 0·02-0·80). Lymphopenia was also observed in most patients with SARS-CoV infection during their course of illness 11, 12 . He et al believed that lymphopenia was a significant factor of SARS-CoV infection and lymphocyte counts may be useful in predicting the disease severity and clinical outcomes 12 . A recent study reported an absolute lymphopenia (lymphocyte count <1·0×10 9 /L) in 63% of patients with SARS-CoV-2 pneumonia on admission. Low levels of total lymphocyte counts were more marked in those patients in which infection resulted in death 10 . A possible cause for the lymphopenia may be that lymphocytes are directly infected and destroyed by SARS-CoV-2. However, this requires further study to confirm, as the cellular receptor for SARS-CoV-2 is angiotensin-converting enzyme 2 13 , which is not expressed on B or T lymphocytes 14 . Therefore, depletion of lymphocytes may be secondary to the direct effect of the virus on the lymphocytes or the effect of various cytokine All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 3, 2020. . https://doi.org/10.1101/2020.06.01.20119032 doi: medRxiv preprint mediated altered lymphocyte trafficking. Since no antiviral treatment for SARS-CoV-2 infection has been proven to be effective, management of this disease remains clinically based and supportive 15 . Considering that acute viral pneumonia is an important cause of acute lung injury (ALI), the value of systematic corticosteroids in patients with SARS-CoV-2 infection is a focus of interest. This study showed patients who received low-to-moderate dose of systematic corticosteroids were less likely to convert to severe cases. In a report by Chen et al 16 , the use of systematic corticosteroids in SARS resulted in reduced mortality and a shorter hospitalization stay, and was not associated with significant secondary lower respiratory tract infection or other complications. However, it is well known that corticosteroid therapy is a double-edged sword 17, 18 . The immune response may be weak and consequently have more difficulty in eradicating the virus because of treatment with systematic corticosteroids 19 . Further studies are urgently required to assess whether systematic corticosteroid treatment is beneficial in patients with SARS-CoV-2 pneumonia. Some limitations of this study should be acknowledged. Firstly, this was a retrospective study with a limited sample size, if the conclusion generalized is to be widely used, it would still need a prospective large-scale clinical validation. Secondly, different varieties of traditional Chinese medicine were administered to most patients, and the effectiveness and potential adverse effects of those drugs given remain largely unknown. Thirdly, examinations of lymphocyte subsets were undertaken in this study, and in addition, total lymphocyte counts were not observed dynamically. Despite the above limitations, we believe that our study has shown important and novel findings about the predictors of severe cases in mild to moderate patients with SARS-CoV-2 pneumonia. To our knowledge, this is the first study that has demonstrated that lymphocyte count is a useful predictor for severity of SARS-CoV-2 pneumonia. This may help clinicians more accurately predict prognosis, and triage All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 3, 2020. . https://doi.org/10.1101/2020.06.01.20119032 doi: medRxiv preprint priorities to improve clinical outcomes. The findings from this study showed that low lymphocyte count (<1·1×10 9 /L) in peripheral blood was an independent risk factor for patients who converted to severe cases. In addition, using of systematic corticosteroids in mild to moderate patients with SARS-CoV-2 pneumonia was associated with a reduced risk of converting to severe cases. Further prospective studies are warranted to confirm these findings. None. All authors declare no competing interests. Muscle soreness 10 (17·2%) 6 (17·1%) 4 (17·4%) All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 3, 2020. Data are n (%), mean (SD) or median (IQR), unless otherwise stated. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 3, 2020. . https://doi.org/10.1101/2020.06.01.20119032 doi: medRxiv preprint Aminotransferase. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 3, 2020. . https://doi.org/10.1101/2020.06.01.20119032 doi: medRxiv preprint All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 3, 2020. . https://doi.org/10.1101/2020.06.01.20119032 doi: medRxiv preprint Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series A Novel Coronavirus from Patients with Pneumonia in China Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding Clinical Characteristics of Coronavirus Disease 2019 in China Clinical features of patients infected with 2019 novel coronavirus in Wuhan Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study Haematological manifestations in patients with severe acute respiratory syndrome: retrospective analysis Effects of severe acute respiratory syndrome (SARS) coronavirus infection on peripheral blood lymphocytes and their subsets Structural basis for the recognition of the SARS-CoV-2 by full-length human ACE2 Exploring the pathogenesis of severe acute respiratory syndrome (SARS): the tissue distribution of the coronavirus (SARS-CoV) and its putative receptor, angiotensin-converting enzyme 2 (ACE2) Understanding SARS-CoV-2-Mediated Inflammatory Responses: From Mechanisms to Potential Therapeutic Tools Treatment of severe acute respiratory syndrome with glucosteroids: the Guangzhou experience On the use of corticosteroids for 2019-nCoV pneumonia Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury The role of adjuvant immunomodulatory agents for treatment of severe influenza We thank Phoebe Jaye Miles for writing assistance and revised of the manuscript.All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted June 3, 2020. . https://doi.org/10.1101/2020.06.01.20119032 doi: medRxiv preprint All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted June 3, 2020. . https://doi.org/10.1101/2020.06.01.20119032 doi: medRxiv preprint All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted June 3, 2020. . https://doi.org/10.1101/2020.06.01.20119032 doi: medRxiv preprint